ASX Share rice
Sun 09 Aug 2020 - 09:26:am (Sydney)

AHZ Share Price

ADMEDUS LTDAHZHealth Care Equipment & Services

AHZ Company Information


Anteris Technologies Ltd




Medical Devices

GIC Industry:

Health Care Equipment & Supplies

GIC Sub Industry:

Health Care Supplies


Toowong Tower Toowong QLD Australia 4066


61 1300 550 310

CEO, Pres, MD & Exec. Director:

Mr. Wayne G. Paterson

Chief Financial Officer:

Mr. Matthew McDonnell

Chief Operating Officer:

Mr. David St. Denis

Gen. Counsel:

Ms. Martha Engel

Chief Medical Officer:

Dr. Kiran Bhirangi

Company Overview:

Admedus Limited, a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells proprietary ADAPT regenerative tissue products; and researches and develops regenerative medicine and immunotherapies. The company was formerly known as Allied Healthcare Group Limited and changed its name to Admedus Limited in November 2013. Admedus Limited is based in Toowong, Australia.

AHZ Share Price Information

Shares Issued:


Dividend Yield:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Profit Margin:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


AHZ CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Change To Inventory:


Change To Account Receivables:


Sale Purchase Of Stock:


Capital Expenditures:


AHZ Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Other Operating Expenses:


Interest Expense:


Total Revenue:


Total Operating Expenses:


Cost Of Revenue:


AHZ Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Retained Earnings:


Other Liabilities:


Other Assets:




Total Current Liabilities:


Short-Term Debt:


Property - Plant & Equipment:


Net Tangible Assets:


Total Current Assets:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Non Currrent Assets (Other):


Short-Term Investments:


Non Current Liabilities (Other):


Non Current Liabilities Total:


AHZ Share Price History

AHZ News

09 Jul, 2020
BRISBANE, Australia and EAGAN, Minn., July 09, 2020 -- Anteris Technologies Limited (ASX:AVR), a structural heart company advancing the DurAVR™ valve, a novel aortic valve.
01 Jun, 2020
Admedus Limited (ASX:AHZ), announced today that it has changed the Company’s name to Anteris Technologies Ltd (“Anteris”). As of May 22, 2020 Anteris, is trading on the Australian Securities Exchange under the ticker AVR. This milestone signifies the completion of Admedus’ restructuring program focused on transitioning to a dedicated structural heart company anchored by ADAPT®, a next generation regenerative bioscaffold platform technology being utilized to address multiple cardiovascular procedures and repairs including, a product (DurAVR™) in development for Transfemoral Aortic Valve Replacement (TAVR) procedures.
12 Apr, 2020
Wayne Paterson has been the CEO of Admedus Limited (ASX:AHZ) since 2016. First, this article will compare CEO...
13 Jan, 2020
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
15 Oct, 2019
Wayne Paterson became the CEO of Admedus Limited (ASX:AHZ) in 2017. First, this article will compare CEO compensation...
13 Oct, 2019
The acquired patches, marketed under the brands CardioCel® and VascuCel®, are processed in a manner that is intended to reduce the risk of calcification.  Annualized 2019 sales of these product lines were $7.1 million, mostly in the US and Europe. Guidance on how this acquisition may affect LeMaitre Vascular’s 2019 revenue, operating income and EPS expectations will be provided at the Company’s Q3 2019 earnings call on October 23, 2019.